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Hepatitis C virus (HCV) is one of the major causative agents of liver diseases, such as liver inflammation, fibrosis, cirrhosis, and
hepatocellular carcinoma. Using an efficient HCV subgenomic replicon system, we demonstrate that transforming growth factor-beta (TGF-h)
suppresses viral RNA replication and protein expression from the HCV replicon. We further show that the anti-viral effect of this cytokine is
associated with cellular growth arrest in a manner dependent on Smad signaling, not mitogen-activated protein kinase (MAPK) signaling.
These results suggest a novel insight into the mechanisms of liver diseases caused by HCV.
D 2004 Elsevier Inc. All rights reserved.
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Hepatitis C virus (HCV), a member of the Flaviviridae
family, is an enveloped virus with a positive single-stranded
9.6-kb RNA genome (Murphy et al., 1995). The virus has
been identified as the major causative agent of non-A, non-
B hepatitis (Choo et al., 1989) that persistently infects
several millions of people throughout the world. Although
acute phase HCV infection is asymptomatic in most cases,
the virus frequently establishes a persistent infection. This
condition is associated with serious clinical diseases,
including chronic hepatitis and liver fibrosis, which can
lead to liver cirrhosis and eventually hepatocellular carci-
noma (Goodman and Ishak, 1995).
Despite the clinical significance, molecular investigation
of the virus has been hampered due to the lack of cell culture
systems that efficiently support HCV replication. In 1999,
the establishment of an HCV subgenomic replicon cell
culture system (Lohmann et al., 1999) improved the
situation. The subgenomic replicon RNA is composed of
the HCV 5V-untranslated region (UTR) containing an0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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transferase (neo) gene, the HCV nonstructural (NS) proteins
3 through 5B under the control of an encephalomyocarditis
virus (EMCV) IRES, followed by the HCV 3V-UTR. The
neo gene is expressed under the control of the HCV IRES,
and thereby, gives the resistance to the cells in which
replicon RNA exists. Instead of the neo gene, the luciferase
gene can be used as a marker. Using the luciferase gene is
beneficial in that it offers easy, speedy, and reliable
detection. As the RNA replicates autonomously in cultured
cells, this replicon system provides a unique tool for the
analysis of the molecular mechanisms of HCV replication
and the screening of anti-HCV compounds.
Transforming growth factor-beta (TGF-h) promotes the
development of liver fibrosis and cirrhosis (Gressner et al.,
2002); serum cytokine levels are associated with the severity
of liver fibrosis in patients with chronic HCV (Nelson et al.,
1997; Neuman et al., 2001; Tsushima et al., 1999). As high
levels of TGF-h expression correlate with chronic hepatitis
and cirrhosis (Calabrese et al., 2003; Shirai et al., 1994),
cytokine serum concentrations serve as useful serologic
markers for hepatitis, cirrhosis, and carcinoma (Song et al.,
2002). Despite accumulating clinical observations, the direct
effect of TGF-h on HCV replication remains unknown.05) 407–417
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cytokine is a multifunctional cytokine that regulates multi-
ple biological functions, including cellular growth inhib-
ition, extracellular matrix (ECM) formation, apoptosis, and
cell differentiation (reviewed in Derynck and Zhang, 2003;
Miyazono et al., 2000). Following receptor ligation, the
activation of receptor-regulated Smad (R-Smad, Smad2, and
Smad3) enhances complex formation with the common-
mediator Smad (Co-Smad, Smad4). These complexes
translocate to the nucleus, where they directly regulate the
transcription of various target genes. TGF-h receptor
ligation also activates members of the mitogen-activated
protein kinase (MAPK) family, including p38 MAPK, c-Jun
N-terminal kinase (JNK), and extracellular signal-regulated
kinase (ERK).
In this study, we demonstrate that TGF-h inhibits HCV
RNA replication and viral protein expression using a HCV
subgenomic replicon system. The anti-viral effect of TGF-h
was associated with growth arrest of cells and the activation
of Smad, not MAPK, signaling. Our results provide insight
into the mechanisms of liver disease pathogenesis caused by
HCV.Results
Construction of a highly efficient and sensitive replicon
system
Although we had previously developed subgenomic HCV
replicon cell lines (Kishine et al., 2002), we desired a highly
efficient replicon system to study the molecular mechanisms
of HCV replication. Among the G418-resistant subgenomic
replicon cell lines, we identified a replicon cell clone (MH14)
in which the viral RNA levels were higher than those in other
replicon cells (Miyanari et al., 2003). The amount of replicon
RNA present in MH14 cells was approximately five times
greater than that present in typical MH5 replicon cells (Fig.
1B). The production of NS5A protein in MH14 cells was also
greater (Fig. 1C), suggesting efficient replication of the viral
RNA. Sequence analysis of replicon RNA in the MH14 cells
revealed two point mutations; S2204R, the replacement of the
Ser residue at position 2204 with Arg, and a silent mutation
L1882L in the NS4B coding region, which did not encode an
amino acid substitution. The S2204R mutation corresponded
to a previously reported adaptive mutation in NS5A
(Lohmann et al., 2003). At least two forms of NS5A, p56
(basally phosphorylated form), and p58 (hyper-phosphory-
lated form), have been reported. Residue Ser-2204 is
important for hyper-phosphorylation of the protein (Tanji et
al., 1995). As expected, only the basally phosphorylated p56
form was detected and hyper-phosphorylated p58 was
missing in the MH14 cells, while MH5 cells, which do not
carry a mutation at the sequences liable for the hyper-
phosphorylation, produce both the p56 and p58 forms of
NS5A (Fig. 1C).To test permissiveness of MH14 cells for HCV repli-
cation, cells were cured of the HCV replicon RNA by
prolonged treatment with IFN-a,resulting in the curedMH14
line (Figs. 1B, C). MH5 replicon cells were treated with
IFN-a in parallel, for use as controls. To examine
permissiveness, cured cells were transfected with replicon
RNAs in which the firefly luciferase gene was inserted (Fig.
1A). We, here, used luciferase gene as a marker since it is
more convenient and has the sensitivity for better quanti-
tation. Cells were harvested at various time points after
transfection and cellular luciferase activities were measured
subsequently (Figs. 1D–F). Luciferase activity in transfected
cells reflects the replication of the replicon RNA. Polymer-
ase-defective RNA replicon constructs, in which the
catalytic GDD motif of the NS5B polymerase was
substituted to the inactive GHD motif, were used as negative
controls. When cells were transfected with the prototype NN
replicon RNA, luciferase activity decreased rapidly 3 to 5
days after transfection (Figs. 1D–F, NN). Use of the MH14
RNA, which is identical to the prototype NN RNA with the
exception of the L1882L and S2204R mutations, resulted in
higher luciferase activities (Figs. 1D–F, MH14) than those
observed in cells transfected with the NN RNA. For the
curedMH14 cells, luciferase activity did not decrease (Fig.
1F, MH14), but increased, peaking 3 to 5 days after
transfection, suggesting highly efficient replication.
We also tested the effect of the mutations and cured cell
lines on G418-resistance transduction efficiencies (not
shown) and confirmed that the numbers of G418-resistant
colonies exhibited a similar trend as seen for the luciferase
activities described above.
These results suggest that the curedMH14 cells were
highly permissive for replication of RNA containing the
adaptive mutations.
Furthermore, when curedMH14 cells were transfected
with the highest efficiency replicon RNA, high luciferase
activity persisted for greater than 1 month (data not shown)
in the absence of selection.
Suppression of HCV replicon with luciferase by TGF-b
As we have constructed a highly efficient and sensitive
replicon system using a luciferase reporter and curedMH14
cells, we used this system to screen anti-HCV compounds.
Treatment for 3 days with IFN-a, IL-1h, or cyclosporin A
reduced the observed luciferase activities to 3.8%, 9.5%, or
3.4% of control levels, respectively (Fig. 2A). As all three
treatments have been reported to repress HCV replicon
(Blight et al., 2000; Watashi et al., 2003; Zhu and Liu,
2003), the system is an effective method to screen for
potential anti-HCV drugs. We also observed the suppressive
effect of TGF-h on luciferase activity (Fig. 2A). While
treatment with 2 ng/ml TGF-h (Fig. 2B, open circle) for 36
h had little effect on luciferase activity, enzymatic activity
decreased to 11%, 12%, 10% that of the mock-treated cells
(black circle) at 48, 60, and 72 h, respectively. To examine
Fig. 1. Constructions and cells used in this study. (A) Schematic representation of the subgenomic replicon RNA constructs. The prototype NNRNAwas used for
transfection to obtain subgenomic replicon cell lines, including MH5 and MH14. NNGHD denotes polymerase-defective mutant, in which the catalytic GDD
motif of the NS5B polymerase was substituted to the inactive GHD motif, and was used as a negative control. MH14 RNA carries two mutations, which were
found in the replicon RNA in MH14 subgenomic replicon cells. MH14GHD is a negative control for the MH14 RNA. The ORFs are depicted as open boxes. The
locations of the mutations introduced into the viral proteins are indicated by vertical lines. (B) Northern blot analysis of total RNA extracted from replicon cells.
RNA from Huh-7, MH14, curedMH14, MH5, or curedMH5 cells was electrophoresed on denaturing agarose gels, blotted, and probed with an HCV RNA (upper
panel). As an internal control, the ethidium bromide-staining pattern of 28S and 18S ribosomal RNA is shown (lower panel). (C) Western blot analysis of NS5A
protein expressed in Huh-7, MH14, curedMH14, MH5, or curedMH5 cells (upper panel). As a control, wild-type NS5A protein was exogenously produced in
Huh-7 cells from an expression plasmid (Huh-7 + pcNS5A). The position of the hyper-phosphorylated form of the protein is designated HyperP. As an internal
control, the Coomassie brilliant blue (CBB) staining pattern of the same blot is shown (lower panel). (D–F) Replication of replicon RNAswith mutations in Huh-7
cells or its derivatives. Huh-7 (D), curedMH5 (E), or curedMH14 (F) cells were transfected with replicon RNA constructs containing the luciferase gene (depicted
in A). Luciferase activity was measured at 1, 3, and 5 days after transfection. Each bar represents the mean and SD of three independent transfections.
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the pCMV-Luc, in which the firefly luciferase gene is driven
under the control of the CMV promoter, was used in Fig.
2C. While TGF-h treatment repressed the luciferase
expression from replicon (Fig. 2B), we found that the
cytokine enhanced the luciferase expression from the CMV
promoter (Fig. 2C), provably because of the activation of
transcriptional factors (Derynck and Zhang, 2003; Miya-
zono et al., 2000).
TGF-h is a multifunctional cytokine that exerts a range
of biological activities, including cell growth inhibition(Derynck and Zhang, 2003; Miyazono et al., 2000). When
exposed to TGF-h, cells generally arrest in the G(1)/S phase
of the cell cycle. We, therefore, examined cell growth of
curedMH14 cells (Fig. 2D). As expected, the growth of
curedMH14 cells was partially inhibited by cytokine treat-
ment (Fig. 2D, open circle). As assessed by FACS,
administration of TGF-h for 2–3 days resulted in G(1)/S-
arrest, while a 1-day treatment had no effect on cell cycle
(Fig. 2E).
Fifty percent suppression of luciferase activity, after 3
days of treatment, was observed in the presence of
T. Murata et al. / Virology 331 (2005) 407–417410approximately 0.1 ng/ml TGF-h (Fig. 2F). Cell growth
started to be suppressed at similar concentrations (Fig. 2G).
Smad-dependent suppression of HCV replicon
The cellular effects of TGF-h are mediated by both type
I and type II serine/threonine kinase receptors. Receptorligation is followed by the activation of both the canonical
Smad and the MAPK signaling pathways, which include
p38 MAPK, JNK, and ERK (Derynck and Zhang, 2003;
Miyazono et al., 2000). To clarify the signaling pathways
crucial for the suppression of HCV replication, we utilized
two constitutive active receptors. One constitutively active
TGF-h type-I receptor, ThR-I(T/D), evokes both Smad and
T. Murata et al. / Virology 331 (2005) 407–417 411MAPK pathways, even in the absence of the TGF-h ligand
(Imamura et al., 1997). The other constitutively active type-I
receptor, ThR-ImL45(T/D), only activates the MAPK
pathways, lacking the ability to excite Smad signaling (Yu
et al., 2002). Three days after transfection of curedMH14
cells with the combination of the luciferase-replicon
(LMH14) RNA and the ThR-I(T/D) expression plasmid,
luciferase activity was reduced to 37% of the control levels,
even in the absence of TGF-h (Fig. 3A). In contrast, co-
transfection with ThR-ImL45(T/D) produces 71% of the
control levels of luciferase activity, suggesting that the
second constitutively active receptor had little effect on
HCV replication (Fig. 3A). As summarized in Figs. 4B and
C, the ThR-I(T/D) receptor likely activated transcription
from promoters containing either AP-1-or Smad-responsive
elements, while the ThR-ImL45(T/D) evoked transcription
from the AP-1-dependent promoter alone. These data serve
as evidence that the antiviral activity of TGF-h is dependent
on Smad signaling.
Upon TGF-h stimulation, R-Smads specific for this
cytokine, Smad2 and Smad3, are activated, forming com-
plexes with the Co-Smad, Smad4, to activate transcription
from the corresponding promoters. As co-expression of
Smad2 with Smad4 or Smad3 with Smad4 mimics the
effects of TGF-h stimulation (Yingling et al., 1997), we
tested if such the co-expression of these molecules would
also suppress HCV replicon production. Transfection of
either Smad2/4 or Smad3/4 reduced the luciferase activity to
16% or 13%, respectively, even in the absence of TGF-h
(Fig. 3A). Expression of an inhibitory-Smad (I-Smad),
Smad7, which inhibits TGF-h mediated Smad signaling
(Derynck and Zhang, 2003), only modestly reduced (81% of
the control) the luciferase activity (Fig. 3A). The enhance-
ment of transcription from AP-1-responsive (Fig. 3C), as
well as TGF-h-responsive (Fig. 3B), promoters by co-
transfection of either Smad2/4 or Smad3/4 was expected, as
Smad4 itself has been reported to elicit transcription from
AP-1 binding site-containing promoters (Liberati et al.,
1999; Yingling et al., 1997).
To verify whether the Smad but not MAPK signaling is
crucial for the suppression of HCV replicon by TGF-h,we
used several specific MAPK inhibitors to examine if the
antiviral effect of TGF-h is associated with the activation of
specific MAPKs. The addition of inhibitors of ERK, p38, orFig. 2. Suppression of luciferase-replicon by TGF-h. (A) curedMH14 cells
administered with DMSO (0.1%), IFN-a (100 IU/ml), IL-1h (10 ng/ml), cyclosp
mEGF (100 ng/ml), TNF-a (10 ng/ml), or IGF-1 (1 ng/ml). Three days later, cel
three independent experiments. (B) curedMH14 cells transfected with LMH14 luc
with TGF-h (2 ng/ml, white circle). At the indicated times, cells were harvested
number. (C) In parallel with the experiments in Fig. 3B, cells transfected with pC
white circle). At the indicated times, cells were harvested for determination of luc
with the experiments in Fig. 3B, cells were mock-treated (black circle) or treate
indicated time points. (E) Flow cytometric analysis of cell cycle progressing in
construct. Cells were incubated in the presence or absence of TGF-h (2 ng/ml) for
in Materials and methods. Dose-dependence of luciferase-replicon (F) and cell grow
replicon RNA construct were treated with varying concentrations of TGF-h fo
determined. The luciferase activity was normalized to cell number and shown wiJNK, U0126, SB20350, or dexamethasone, respectively, did
not cancel TGF-h suppression of luciferase activity (Fig.
4A), despite effective inhibition of kinase activity by the
inhibitors (Figs. 4B–D). The phosphorylation of ERK by
TGF-h was not observed under these conditions (Fig. 4B),
as ERK was already activated by growth factors contained
within the bovine serum supplementing the culture medium.
Suppression of G418-resistant replicon by TGF-b
We then investigated the effect of TGF-h on G418-
resistant replicon RNA or protein levels. MH14, G418-
resistant subgenomic replicon cells, were treated with IFN-
a, TGF-h, or BMP-4. BMP-4 was used here because it is a
member of TGF-h superfamily cytokines and it does not
induce inhibition of cell proliferation at least in Huh-7 cells.
Total RNA and protein were collected at various time
points. RNAs were subjected to Real-Time RT-PCR (Fig.
5A) or Northern blotting (Fig. 5B), while proteins were
examined by Western blotting (Fig. 5C). Replicon RNA
levels gradually decreased following treatment with 2 ng/ml
TGF-h to 0.6% of the levels observed in mock-treated
samples on the 7th day. This inhibition was similar to that
seen following treatment with 100 IU/ml IFN-a. The NS5A
protein was virtually undetectable by the 5th day after
transfection (Fig. 5C). The suppressive effect of TGF-h on
viral protein production was also observed by indirect
immunofluorescence (not shown).
Because the replicon RNA of MH14 cells has the EMCV
IRES to produce NS proteins, one could not deny the
possibility that the EMCV IRES might cause the inhibition
by TGF-h. Therefore, we next used full-genome replicon
cell line SNC#2 (Fig. 6), which has the HCV IRES instead
of the EMCV IRES, and tested if TGF-h would affect the
replication. As shown in Fig. 6B, replicon RNA in SNC#2
cells treated with TGF-h decreased clearly while BMP-4 did
not suppress the RNA levels.
Simultaneous suppression of viral RNA replication and
protein synthesis by TGF-b
The suppression of HCV replication by TGF-h treatment
was associated with the inhibition of cell growth. We
examined the kinetics of the suppression of HCV replicationtransfected with the luciferase-replicon RNA construct (LMH14), were
orin A (1 Ag/ml), TGF-a (1 ng/ml), TGF-h (2 ng/ml), BMP-4 (10 ng/ml),
lular luciferase activity was measured. Bars represent the mean and SD of
iferase-replicon RNA construct were mock-treated (black circle) or treated
for determination of luciferase activity. The activity was normalized to cell
MV-Luc were mock-treated (black circle) or treated with TGF-h (2 ng/ml,
iferase activity. The activity was normalized to cell number. (D) In parallel
d with TGF-h (2 ng/ml, white circle). Cell numbers were counted at the
curedMH14 cells transfected with the S2204R luciferase-replicon RNA
1, 2, or 3 days. The DNA content of these cells was analyzed as described
th inhibition (G). curedMH14 cells transfected with the LMH14 luciferase-
r 3 days. Luciferase activity (F) and cell number (G) were subsequently
th the SD value of three experiments in F.
Fig. 3. Expression of TGF-h signaling-related proteins affected HCV
replicon. curedMH14 cells were transfected with the expression plasmid
designated below panel C together with (A) the luciferase-replicon construct
with the mutations (LMH14), (B) p3TP-Luc, to monitor Smad-dependent
transcription, or (C) pAP1-Luc, used to monitor AP-1-dependent tran-
scription. Four hours after transfection, TGF-h (2 ng/ml) was added. Cells
were incubated with or without the cytokine for 3 days (A) or 12 h (B, C) and
then cellular luciferase activity was measured. The luciferase activity in A
was normalized to cell number and then, the mean and SD value of three
transfections are shown.
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various times after the inoculation of replicon cells with the
cytokine (Fig. 7). Aphidicolin and IFN-a were used ascontrols. The inhibition of viral protein synthesis by 100 IU/
ml IFN-a began 12 h after treatment, while viral RNA
synthesis was not affected until 24 h after cytokine addition.
These results suggest that IFN-a first represses protein
synthesis, thereby blocking RNA replication. In contrast,
both aphidicolin and TGF-h inhibited protein synthesis and
RNA replication concurrently, by 48 h after treatment. As
both aphidicolin and TGF-h have growth inhibitory effects
on cells, it is likely that both prevent HCV replicon in
similar manners.
Anti-HCV activity of TGF-b was not mediated by
IFN-induced signaling pathway
Although the antiviral activity of TGF-h was dependent
on Smad signaling, the possibility remains that TGF-h may
exert an antiviral activity via the same mechanisms as IFN-a
and -g. The binding of IFN-a or -g to cellular receptors
activates the JAK tyrosine kinase, which in turn phosphor-
ylates effector Stat proteins. These proteins stimulate
transcription from promoters with the specific sequences,
ISRE or GAS, respectively. We prepared reporter plasmids
that produce firefly luciferase following IFN-a or -g
stimulation by placing the gene under the control of a
promoter containing either ISRE or GAS sequence. While
100 IU/ml IFN-a stimulation enhanced transcription from
the ISRE-promoter 3.5-fold, enhancement of promoter
activity was not observed following TGF-h treatment (Fig.
8A). The addition of 1000 IU/ml IFN-g activated the GAS-
dependent promoter by 5.8-fold, while TGF-h had little
effect (Fig. 8B). The results suggest that TGF-h exerts its
antiviral activity in a manner independent of IFN signaling.Discussion
First, we have developed an efficient HCV subge-
nomic replicon system in this study. When maintained in
cells, HCV replicon RNA often acquires cell culture-
adaptive mutations. We found that the replicon RNA in
MH14 cells carries two mutations, L1882L and S2204R.
Among them, the S2204R, but not the L1882L, mutation
was necessary and sufficient for the high efficiency (not
shown). Although the mechanism by which the adaptive
mutation produce high replication efficiency is not
known, the interaction of the NS5A protein with a co-
factor, such as hVAP-A (Gao et al., 2004; Tu et al.,
1999), might explain the phenomenon.
As cytokines can play major roles in pathogenetic
process during the courses of viral diseases, the relation-
ships between viruses and cytokines, such as TGF-h, are of
great importance. In this study, we found that TGF-h
inhibits viral RNA replication and protein expression in the
HCV replicon system.
The mechanism by which IFN-a suppresses HCV
replicon is not well understood. Here, we showed that
Fig. 4. Effect of MAPKs on the HCV replicon. (A) curedMH14 cells transfected with the luciferase-replicon construct (LMH14) were treated with DMSO,
TGF-h (2 ng/ml) plus DMSO, or TGF-h (2 ng/ml) with either U0126 (3 AM), SB203580 (30 AM), or dexamethasone (1 AM). Inhibitors were added 1 h prior to
the addition of TGF-h . After a 3-day treatment, cellular luciferase activity was measured. The mean and SD of three independent transfections are depicted
after normalization to cell number. (B–D) The effect of inhibitors on the phosphorylation of ERK (B), p38MAPK (C), and JNK (D). Western blotting examined
the phosphorylation of these molecules in cells treated with or without the designated reagents. The upper panels depict phosphorylated MAPKs, while the
middle panels display the total amount of the MAPKs. CBB staining pattern of the same blot is used as a loading control (lower panel).
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RNA replication of the HCV replicon (Fig. 7). These data
seem to support the previous report (Guo et al., 2004)
and may aid our understanding of the suppression
mechanism by IFN-a. IFN-a might suppress HCV trans-
lation trough the La (Shimazaki et al., 2002)-, ISG56
(Sumpter et al., 2004) or PKR (Wang et al., 2003)-dependent
manner.
In contrast, either aphidicolin or TGF-h simultaneously
inhibited both protein synthesis. and RNA replication
from the replicon de novo (Fig. 7). While the mechanism
of simultaneous suppression by aphidicolin or TGF-h
remains unknown, both reagents arrest cell cycle pro-
gression at G(1)/S, suggesting a common target in the
repression of HCV replicon expression. Recently, Scholle
et al. (2004) reported that the replication of the HCV
replicon RNA depends on host cell growth. Our resultsFig. 5. Suppression of G418-resistant subgenomic replicon by TGF-h. (A) MH14,
with BMP-4 (10 ng/ml), TGF-h (2 ng/ml), or IFN-a (100 IU/ml) for 1, 3, 5, or 7
RNAwas determined by real-time RT-PCR analysis. (B) Total RNAwas also subje
pattern of ribosomal RNA is shown as an internal control (lower panel). (C) Total p
cytokine treatment. Western blot analysis was performed using an antibody against
(lower panel).clearly correspond with that report, in which viral RNA
levels remained unchanged during a 24-h period of cell
cycle arrest followed by drops by 48 h.
It has been demonstrated that cell cycle arrest by TGF-h
is mainly caused in the Smad pathway-dependent manner
and the MAPK signaling serves as an accessory modifier of
the arrest (Ten Dijke et al., 2002). Therefore, our result is
convincing in that Smad, but not the MAPK pathway,
played an essential role in the suppression of HCV
replication.
Broadly speaking, serological investigations of HCV in
chronically infected patients imply an inverse relationship
between viral RNA load and TGF-h levels. Increased
TGF-h expression significantly correlates with the degree
of hepatic fibrosis (Calabrese et al., 2003; Nelson et al.,
1997). A 3-year follow-up study demonstrated that TGF-
h levels were elevated in patients with fibrosis that wasa G418-resistant subgenomic replicon cell line, was mock-treated or treated
days. Following the extraction of total RNA, the quantity of HCV replicon
cted to Northern blot analysis (upper panel). The ethidium bromide-staining
rotein from cells prepared as above was harvested after either 3 or 5 days of
NS5A. CBB staining pattern of the same blot is shown as a loading control
Fig. 6. Suppression of G418-resistant replicon without EMCV IRES by TGF-h. (A) Schematic representation of an RNA construct in typical subgenomic
replicon cells (upper) and that in SNC#2 replicon cells (lower). RNA in SNC#2 carries the sequence for the whole HCV ORFs, driven by the HCV IRES
instead of the EMCV IRES. The ORFs are depicted as open boxes. (B) SNC#2 cells were mock-treated or treated with BMP-4 (10 ng/ml), TGF-h (2 ng/ml), or
IFN-a (100 IU/ml) for 1, 3, 5, or 7 days. Following the extraction of total RNA, the quantity of HCV replicon RNA was determined by real-time RT-PCR
analysis.
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correlated with lower levels of viremia in patients than
those with less progressed fibrosis (Adinolfi et al., 2001).
These reports suggest that the presence of TGF-h, which
may be induced by HCV core protein (Taniguchi et al.,
2004), has a suppressive influence on viral RNA load.
Gewaltig et al. (2002) demonstrated that polymorphisms
in the TGF-h gene were associated with progression of
HCV-induced liver fibrosis, suggesting again that the
cytokine and the cytokine signaling have a certain
influence on the virus.
The precise molecular mechanism of the anti-HCV
activity of TGF-h remains to be clarified. Additional
studies, including clinical studies, may reveal a novel
mechanism of HCV replication regulation, potentially
providing a target for novel anti-HCV therapies in the
future.Fig. 7. Simultaneous suppression of viral RNA replication and protein synthesis by
mock-treated or treated with TGF-h (2 ng/ml), aphidicolin (5 Ag/ml), or IFN-a (10
intact replication assay (A) or [35S]-methionine metabolic labeling and immunopr
methods.Materials and methods
Cell culture, antibodies, and reagents
Huh-7, curedMH5, and curedMH14 cells were main-
tained in Dulbecco’s modified Eagle medium (Gibco BRL)
supplemented with 10% fetal bovine serum, 100 units/ml
nonessential amino acids (Invitrogen), and 100 Ag/ml of
both penicillin and streptomycin sulfate (Invitrogen). MH5,
MH14, and SNC#2 replicon cells were cultured in the above
medium supplemented with 300 Ag/ml G418 (Geneticin,
Invitrogen). Cured cells were prepared by treating cells with
5000 IU/ml of IFN-a for 2 weeks. Absence of replicon
RNA and viral proteins was checked by Northern blotting,
Western blotting, and RT-PCR.
Rabbit antisera raised against p38, JNK, ERK, and
phospho-ERK were purchased from Cell Signaling Tech-TGF-h. (A, B) MH14, a G418-resistant subgenomic replicon cell line, was
0 IU/ml) for 12, 24, 36, 48, 60, or 72 h. Cells were then subjected to semi-
ecipitation using an anti-NS5A antibody (B) as described in Materials and
Fig. 8. TGF-h exerts an anti-HCV activity independent of the signal
transduction pathway activated by IFN-a or -g. curedMH14 cells were
transfected with either pISRE-Luc (A), pGAS-Luc (B) or p3TP-Luc (C) and
treated with TGF-h (2 ng/ml), IFN- (100 IU/ml), or IFN-g (1000 IU/ml).
Luciferase activities were measured 12 h after transfection. Data represent
the means and SD values of relative luciferase activities in three
independent experiments.
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phospho-JNK were acquired from BD Biosciences and
SIGMA, respectively. Horseradish peroxidase-conjugated
goat antibodies to mouse and rabbit IgG were procured from
Amersham Biosciences. TGF-h, BMP-4, and SB203580
were obtained commercially from Calbiochem. U0126 and
Dexamethasone were purchased from SIGMA.
Northern and Western blot analysis
RNAwas extracted from cells using Sepasol RNAI super
reagent (Nacalai Tesque, Kyoto, Japan) according to the
manufacturer’s protocol. Northern blot analysis was per-
formed as described (Kishine et al., 2002). The 1.5-kb
EcoRI fragment of pNNRZ2 was used, which corresponds
to the C-terminal half of the NS5A gene and the N-terminal
half of the NS5B gene as a probe.
Plasmid construction
pNNRZ2 was used to prepare G418-resistant prototype
NN replicon RNA (Kishine et al., 2002). To generate
pMH14, L1882L and S2204R mutations in NS4B and
NS5A were inserted into pNNRRZ2 by PCR-based site-
directed mutagenesis. The following primers were used
for mutagenesis: 5V-CTGGTCAATCTACTTCCTGCC-3V
and 5V-GGCAGGAAGTAGATTGACCAG-3V (Bold letters
in the primers denote the substituted nucleotides for
L1882L). 5V-CTTCAGCTAGACAGTTGTCTGC-3V and
5V-GCAGACAACTGTCTAGCTGAAG-3V (same for
S2204R). In addition, 5V-CACCCAAATGTACACC-
AATG-3V and 5V-CGATCCTCATGGAACCGTTC-3V, 5V-
GAACGGTTCCATGAGGATCG-3V, and 5V-TGATGGG-
CAGCTTGCTTTCC-3V were used for amplification of
appropriate fragments. The neo genes in pNNRZ2 and
pMH14 were replaced with the luciferase gene from thepGL3 vector (Promega, Tokyo, Japan) to create pLNNRZ2
and pLMH14. To prepare the NS5B (RNA polymerase)-
defective luciferase-replicon constructs, we inserted a GHD
motif into either pLNNRZ2 or pLMH14 by replacing the
corresponding sequence with pNNRZ2GHD (Kishine et
al., 2002) to create pLNNRZ2GHD or pLMH14GHD,
respectively. pSNC was generated to prepare G418-
resistant full-genome replicon cell line, SNC#2. To prepare
the plasmid, the sequence from NS3 to the end of the
NS5B was cloned from I377NS3-3V (Lohmann et al.,
1999) with the S2204I adaptive mutation and other parts
were from pM1LE (Kishine et al., 2002).
The coding region for NS5A in the pNNRZ2 plasmid
was cloned into the SmaI site of pCALNL5/pBR (kindly
provided by Dr. M. Kohara, Tokyo Metropolitan Institute of
Medical Science). The neomycin-resistance gene was
removed by XhoI digestion to prepare the expression vector
pcNS5A.
pcDNA3 (Invitrogen)-based plasmids expressing FLAG-
tagged human Smad2 or Smad4, HA-tagged constitutively
active TGF-h type I receptor (ThR-I[T/D]), and p3TP-Luc
have been described previously (Ohshima and Shimotohno,
2003; Imamura et al., 1997). The combined mutant type I
receptor, R-ImL45(T/D), which possesses a constitutively
active kinase domain, but lacks the ability to phosphorylate
Smad, was generated by PCR-based mutagenesis as
described (Ohshima and Shimotohno, 2003; Yu et al.,
2002). The pAP1-Luc reporter plasmid was obtained
commercially (PathDetect Reporter System; Stratagene,
LaJolla, CA). Two additional reporter plasmids, pISRE
(IFN-a-stimulated response element)-Luc and pGAS
(gamma activation site)-Luc, were based on pGL3-Promoter
Vector (Promega, Tokyo, Japan) that contains the SV40
basal promoter sequence without an enhancer sequence. To
create pISRE-Luc, the ISRE consensus sequence (ACTTT-
CAGTTTCAT) was repeated five times in tandem and
inserted between the MluI and XhoI cloning sites of the
pGL3-Promoter vector. For pGAS-Luc, three tandem
repeats of the GAS sequence (TTTCCCCGAAA) were
cloned into the pGL3-Promoter Vector at the KpnI–BglII
cleavage site.
RNA synthesis
HCV subgenomic RNA was transcribed in vitro using a
MEGAscript T7 kit (Ambion) according to the manufactur-
er’s instructions. Following DNase treatment, RNA was
purified by lithium chloride precipitation.
Transfection and luciferase assay
For the luciferase assay to monitor luciferase-replicon,
curedMH14 or other cells seeded on 48-well plate (5  103
cells/well) were transfected with 0.25 Ag of the luciferase-
replicon RNA using DMRIE-C reagent (Invitrogen) accord-
ing to the manufacturer’s instructions. Proteins in cells were
T. Murata et al. / Virology 331 (2005) 407–417416extracted in a lysis buffer supplied in a Dual-Luciferase
Reporter Assay System (Promega) kit and the luciferase
activity was measured using the kit. Assays were performed
in triplicate; standard deviations are denoted by bars in the
figures. Plasmid DNA was transfected into cells using
FuGENE6 reagent (Roche).
Real time RT-PCR analysis
To monitor the effect of cytokines on neo-resistant
replicon RNA, TGF-h, IFN-a, or BMP-4 was added in
the media of replicon cells seeded on 6-well plate (4  10 4
cells/well). At various times, total cellular RNA was
collected and subjected to Real time RT-PCR analysis.
The 5V-UTR of HCV genomic RNA was quantified using
the ABI PRISM 7700 sequence detector (Applied Bio-
systems) as described (Watashi et al., 2003) using the
5V-CGGGAGAGCCATAGTGG-3V (forward) and 5V-
AGTACCACAAGGCCTTTCG-3V (reverse) primers and
the fluorogenic probe 5V-CTGCGGAACCGGTGAGTA-
CAC-3V. As an internal control, ribosomal RNA was
quantified using TaqMan ribosomal RNA control reagents
(Applied Biosystems).
Flow cytometry analysis Cells were trypsinized, fixed in
formaldehyde, washed with PBS, and treated with staining
solution containing 50 Ag/ml propidium iodide (PI) (Sigma),
50 Ag/ml of RNaseA (Wako), and 0.1% Triton X-100
(nacalai tesque) in PBS for 15 min. PI fluorescence was
analyzed using a FACScalibur flow cytometer (Becton
Dickinson). Twenty thousand events were collected and
analyzed using CellQuest software (Becton Dickinson).
Semi-intact cell replication assay
A semi-intact cell replication assay was performed as
described (Miyanari et al., 2003). In brief, cells were
permeabilized by incubation in reaction buffer containing
digitonin. Following two washes, samples were incubated
for 4 h in the labeling reaction mixture containing 10 ACi of
[32P]UTP (Amersham Biosciences) in reaction buffer at 27
8C. Total cellular RNA was collected and fractionated by
denaturing agarose gel electrophoresis. Radioactivity incor-
porated into newly synthesized replicon RNA was visual-
ized using a Fujix Bio-Imaging Analyzer BAS2000 System
(Fuji Photo Film, Japan).
Metabolic labeling and immunoprecipitation of NS5A
protein
Cells were washed in PBS and incubated in methionine-
free DMEM (ICN biomedicals) containing 10% dialyzed
FBS and 100 AC i/ml of [35S]-methionine (Tran 35S label,
ICN biomedicals) for 4 h. After washing in PBS, cells were
lysed in RIPA buffer (10 mM Tris–HCl pH 7.4, 1% NP40,
0.1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, and
1 mM EDTA) for 1 h. Cellular debris was removed bycentrifugation at 15,000 rpm for 10 min. Following pre-
clearing, lysates were incubated with a monoclonal antibody
against NS5A in the presence of protein-G sepharose. After
extensive washing, immune complexes were recovered by
low-speed centrifugation and subjected to SDS-PAGE.
Radioactivity incorporated into newly synthesized NS5A
protein was visualized using a Fujix Bio-Imaging Analyzer
BAS2000 System (Fuji Photo Film, Japan).Acknowledgments
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